vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $139.2M, roughly 4.3× ADMA BIOLOGICS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 35.5%, a 5.4% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 18.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
ADMA vs EXEL — Head-to-Head
Income Statement — Q4 2025 vs Q4 2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $598.7M |
| Net Profit | $49.4M | $244.5M |
| Gross Margin | 63.8% | 95.6% |
| Operating Margin | 45.1% | 39.3% |
| Net Margin | 35.5% | 40.8% |
| Revenue YoY | 18.4% | 5.6% |
| Net Profit YoY | -55.9% | 74.8% |
| EPS (diluted) | $0.20 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | $139.2M | $597.8M | ||
| Q3 25 | $134.2M | $568.3M | ||
| Q2 25 | $122.0M | $555.4M | ||
| Q1 25 | $114.8M | $566.8M | ||
| Q4 24 | $117.5M | — | ||
| Q3 24 | $119.8M | $539.5M | ||
| Q2 24 | $107.2M | $637.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | $49.4M | $193.6M | ||
| Q3 25 | $36.4M | $184.8M | ||
| Q2 25 | $34.2M | $159.6M | ||
| Q1 25 | $26.9M | $139.9M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $118.0M | ||
| Q2 24 | $32.1M | $226.1M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | 63.8% | 96.9% | ||
| Q3 25 | 56.3% | 96.6% | ||
| Q2 25 | 55.1% | 96.5% | ||
| Q1 25 | 53.2% | 96.5% | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | 96.8% | ||
| Q2 24 | 53.6% | 97.2% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | 45.1% | 39.6% | ||
| Q3 25 | 38.0% | 37.6% | ||
| Q2 25 | 35.1% | 33.6% | ||
| Q1 25 | 30.4% | 28.8% | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | 25.2% | ||
| Q2 24 | 36.6% | 43.3% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | 35.5% | 32.4% | ||
| Q3 25 | 27.1% | 32.5% | ||
| Q2 25 | 28.1% | 28.7% | ||
| Q1 25 | 23.4% | 24.7% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 21.9% | ||
| Q2 24 | 29.9% | 35.5% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $0.20 | $0.69 | ||
| Q3 25 | $0.15 | $0.65 | ||
| Q2 25 | $0.14 | $0.55 | ||
| Q1 25 | $0.11 | $0.47 | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | $0.40 | ||
| Q2 24 | $0.13 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $1.1B |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $2.2B |
| Total Assets | $624.2M | $2.8B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $87.6M | $988.5M | ||
| Q3 25 | $61.4M | $791.1M | ||
| Q2 25 | $90.3M | $1.0B | ||
| Q1 25 | $71.6M | $1.1B | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | $1.2B | ||
| Q2 24 | $88.2M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $477.3M | $2.2B | ||
| Q3 25 | $431.2M | $2.0B | ||
| Q2 25 | $398.3M | $2.1B | ||
| Q1 25 | $373.4M | $2.2B | ||
| Q4 24 | $349.0M | — | ||
| Q3 24 | $231.9M | $2.3B | ||
| Q2 24 | $188.3M | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $624.2M | $2.8B | ||
| Q3 25 | $568.7M | $2.7B | ||
| Q2 25 | $558.4M | $2.8B | ||
| Q1 25 | $510.6M | $2.9B | ||
| Q4 24 | $488.7M | — | ||
| Q3 24 | $390.6M | $3.0B | ||
| Q2 24 | $376.4M | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $333.5M |
| Free Cash FlowOCF − Capex | $34.6M | $332.4M |
| FCF MarginFCF / Revenue | 24.8% | 55.5% |
| Capex IntensityCapex / Revenue | 0.8% | 0.2% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $35.6M | $290.3M | ||
| Q3 25 | $13.3M | $49.0M | ||
| Q2 25 | $21.1M | $211.4M | ||
| Q1 25 | $-19.7M | $240.3M | ||
| Q4 24 | $50.2M | — | ||
| Q3 24 | $25.0M | $271.3M | ||
| Q2 24 | $45.6M | $119.5M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | $34.6M | $288.8M | ||
| Q3 25 | $-1.1M | $46.2M | ||
| Q2 25 | $18.7M | $208.5M | ||
| Q1 25 | $-24.4M | $236.3M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | $263.1M | ||
| Q2 24 | $43.6M | $113.0M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | 24.8% | 48.3% | ||
| Q3 25 | -0.8% | 8.1% | ||
| Q2 25 | 15.3% | 37.5% | ||
| Q1 25 | -21.2% | 41.7% | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | 48.8% | ||
| Q2 24 | 40.7% | 17.7% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | 0.8% | 0.2% | ||
| Q3 25 | 10.7% | 0.5% | ||
| Q2 25 | 2.0% | 0.5% | ||
| Q1 25 | 4.1% | 0.7% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | 1.5% | ||
| Q2 24 | 1.9% | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | 0.72× | 1.50× | ||
| Q3 25 | 0.36× | 0.27× | ||
| Q2 25 | 0.62× | 1.32× | ||
| Q1 25 | -0.73× | 1.72× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 2.30× | ||
| Q2 24 | 1.42× | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
